TerminatedPhase 2NCT02104336
Phase 2 Study of EPI-743 in Children With Pearson Syndrome
Studying Pearson syndrome
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Edison Pharmaceuticals Inc
- Principal Investigator
- Matthew Klein, MD, FACSEdison Pharmaceuticals
- Intervention
- EPI-743(drug)
- Enrollment
- 2 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2014 – 2016
Study locations (4)
- Children's Hospital of Orange County, Orange, California, United States
- Cleveland Clinic, Cleveland, Ohio, United States
- Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States
- Baylor College of Medicine, Houston, Texas, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02104336 on ClinicalTrials.govOther trials for Pearson syndrome
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT06017869Evaluate the Safety and Therapeutic Effects of a Single Intravenous Infusion (IV) of Autologous CD34+ Cells Enriched With Allogenic Placenta-derived Mitochondria in Patients With a Diagnosis of Pearson Syndrome (PS)Minovia Therapeutics Ltd.
- RECRUITINGNCT05554835Global Registry and Natural History Study for Mitochondrial DisordersLMU Klinikum